To View These Headlines and More Visit the Yahoo Link Above
(Global Exposure-New Contract-Potential-An Honor)
** Could result in $32 Million in Revenue over 5 Years !!
OxySure and Z-Medica Sign Distribution AgreementMarketwired(Mon, Jun 15)
(Emergency Medical Market Exposure-New Product)
** New Distribution Partner !!
OxySure Unveils Plans to Add Drones for Emergency UseMarketwired(Tue, Jun 2)
(Military-EMS-Search & Rescue-Humanitarian Aid)
(Zero Manufacturing Costs-Cost Built Into Package)
(Purchasers Assume-Cover Manufacturing Costs)
** $3,000 - $7,000 Approx per Make/Model and Payload REVENUE Potential is Huge !!
OxySure Territorial Sales Managers 25-30 By Year End 2015
(Appointments/Training Could Leak Into Q1 2016)
(Minimum Quota Per TSM $500,000 Per Year)
** Minimum 25 TSM's/Minimum Quota Met $500K each = $12.5 Million New Revenue 2016 !!
We Believe OXYS is a LONG PLAY with Short Term Gain Potential
Advantageous Entry or Cost Average Level
OXYS "Saving Lives Daily"
** Should you want or need more information please contact us :
** To View These Headlines and More Visit the Yahoo Link Above
Regen BioPharma Dually Trades on the (OTCBB) & (OTCPINK)
What makes Regen BioPharma and attractive situation ? And why you should seriously take a closer look:
RGBP was selected and accepted for presentation at the (what is considered to be the "Premier" Conference/Society for Stem Cell research) International Society for Stem Cell Research Annual Meeting, June 24-27, in Stockholm, Sweden.
RGBP "Patented" New Drugs and the recent announcement of a "Filing" for a New "Patent" on a Drug geared towards treating "Leukemia.
RGBP brought on an "Expert" in the field of Cancer Research, who possibly could be instrumental in answering the "Final/Last Phase" of clinical trials and queries from the FDA prior to clearance/approval of dCellVax (treatment for Breast Cancer).
RGBP has "Engaged" Charles River Laboratories to initiate a Good Laboratory Practices <GLP> mouse toxicity study with regards to "HemaXellerate". HemaXellerate, a therapy under development by Regen, is a cellular drug designed to heal damaged bone marrow. That could be the "Last Step" prior to FDA clearance/approval for HemaXellerate.
RGBP a "Prime Candidate" to be bought out by a "Larger Pharma" ? (Chief Scientific Director Thomas Ichim PhD was CEO of Medi Stem when it was bought out for $26 Million)
** We think all of the above apply to the situation !! And that this virtually "Unknown Sleeper" will one day be the "Leader" in the Breast/Cancer-Rare Blood Disorder /Disease Stem Cell Sector. You know the old saying get in low, sell high.
**We believe Regen BioPharma is a LONG PLAY, with SHORT Term GAIN Potential.
> If you have any questions, please feel free to contact us.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.